Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...
Results of progression-free survival (PFS) and updated interim overall survival (OS) analyses from the phase 3 BREAKWATER study show that the combination of dual-targeted therapies encorafenib and ...
Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results